Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

Erlotinib (Tarceva™, OSI-774), a potent epidermal growth factor receptor tyrosine kinase inhibitor (EGFR), was evaluated in a phase II study to assess its activity in patients with metastatic colorectal cancer. In all, 38 patients with metastatic colorectal cancer were treated with erlotinib at a co...

Descripción completa

Detalles Bibliográficos
Autores principales: Townsley, C A, Major, P, Siu, L L, Dancey, J, Chen, E, Pond, G R, Nicklee, T, Ho, J, Hedley, D, Tsao, M, Moore, M J, Oza, A M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361254/
https://www.ncbi.nlm.nih.gov/pubmed/16570047
http://dx.doi.org/10.1038/sj.bjc.6603055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361254/
https://www.ncbi.nlm.nih.gov/pubmed/16570047
http://dx.doi.org/10.1038/sj.bjc.6603055

Ejemplares similares